Adoptive cell therapy for acute myeloid leukemia. Issue 6 (12th May 2019)

• Record Type: Journal Article
• Authors: Ma, Hongbing; Padmanabhan Iyer, Swaminathan; Parmar, Simrit; Gong, Yuping
• Is Part Of: Leukemia & lymphoma. Volume 60:Issue 6(2019)
• Page Start: 1370
• Page End: 1380
• Publication Date: 2019-05-12
• Subjects: Acute myeloid leukemia -- cell therapy -- immunotherapy; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2018.1553300
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Acute myeloid leukemia (AML) is the most common tumor in adult patients, most of the patients have a poor prognosis even after high-intensity chemotherapy, especially for relapsed, refractory or elderly patients. Therefore, new methods are needed to change the outcomes. In recent years, an increasing number of immune-therapies are emerging where adoptive cell therapy, a special immunotherapy, has become a promising strategy for AML. Here, we review the clinical application and advancement of donor lymphocyte infusion, chimeric-antigen receptor (CAR) T cell therapy, natural killer (NK) cell therapy and dendritic cell vaccination for AML, hopefully providing an overview of clinical aspects of advances in adoptive cell therapy for AML.